FDA Inspection 1275696 — Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.
The FDA completed an inspection of Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. on February 20, 2020 in Singapore. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 20, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Singapore (Singapore)
Additional Details
Mutual Recognition Agreement (MRA)